YahooSeptember 18, 2026 at 2:34 PM NYLast Month
Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.
Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.’
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
